TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced its participation in two upcoming investor conferences:
- Canaccord Genuity Rare Disease, BioPharma 1x1 Day
Tuesday, February 2, 2016
Omni Berkshire Place Hotel, New York, NY
- SunTrust Robinson Humphrey 2016 Orphan Drug Day
Tuesday, February 23, 2016
JW Marriott Essex House, New York, NY
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, with an initial focus on immunotherapy and oncology. Atara Bio’s programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 [email protected] Media: Justin Jackson 212-213-0006 x327 [email protected]
